Literature DB >> 6322545

Nicotinic acid and its derivatives: a short survey.

W Hotz.   

Abstract

Nicotinic acid is used widely in the treatment of hyperlipoproteinemias and reduces both the cholesterol and the triglyceride concentrations in the plasma. However, very high doses are needed to achieve these therapeutic effects, which is why side effects are common and are particularly known to hinder the compliance of patients. Nicotinic acid derivatives have been developed to overcome this problem. As a result of chemical and galenic retardation, these derivatives lessen the side effects and the necessary doses are considerably reduced in comparison with pure nicotinic acid. However, most of these derivatives are not pure prodrugs, and exert their own synergistic pharmacokinetic and pharmacodynamic effects. In general, when nicotinic acid and its derivatives are used in therapy a desirable modification of the composition of the plasma lipids in the sense of an antiatherosclerotic activity can be expected (reductions of VLDL and LDL and an increase of HDL). Good possibilities for using nicotinic acid in the prevention and remission of atherosclerotic processes arise in connection with the activation of fibrinolysis and the reduction of the tendency toward platelet aggregation. In the light of recent studies on the mechanisms of action of nicotinic acid, an influence on the prostaglandin system has been found, as a result of which an interconnection between its various effects and side effects appears to be possible.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6322545

Source DB:  PubMed          Journal:  Adv Lipid Res        ISSN: 0065-2849


  5 in total

1.  GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.

Authors:  Zoltán Benyó; Andreas Gille; Jukka Kero; Marion Csiky; Marie Catherine Suchánková; Rolf M Nüsing; Alexandra Moers; Klaus Pfeffer; Stefan Offermanns
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects.

Authors:  X Chen; N Iqbal; G Boden
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

3.  New nicotinic acid-based 3,5-diphenylpyrazoles: design, synthesis and antihyperlipidemic activity with potential NPC1L1 inhibitory activity.

Authors:  Mai E Shoman; Moustafa O Aboelez; Montaser Sh A Shaykhon; Sanaa A Ahmed; Gamal El-Din A Abuo-Rahma; Omar M Elhady
Journal:  Mol Divers       Date:  2020-02-17       Impact factor: 2.943

4.  The role of HCA2 (GPR109A) in regulating macrophage function.

Authors:  Kambiz Zandi-Nejad; Ayumi Takakura; Mollie Jurewicz; Anil K Chandraker; Stefan Offermanns; David Mount; Reza Abdi
Journal:  FASEB J       Date:  2013-07-23       Impact factor: 5.191

Review 5.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.